Semaglutide is a synthetic analog of the glucagon‐like peptide‐1 (GLP‐1) receptor agonists, primarily utilized in managing type 2 diabetes mellitus following its approval for injectable use in December 2017 [1]. This evidence concerns the gene GLP1R and diabetes mellitus.